Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;201(2):171-181.
doi: 10.1007/s10549-023-07014-x. Epub 2023 Jul 12.

Molecular features of androgen-receptor low, estrogen receptor-negative breast cancers in the Carolina breast cancer study

Nikita D Jinna #  1 , Sarah Van Alsten #  2 , Padmashree Rida  3 , Victoria L Seewaldt  4 , Melissa A Troester  2
Affiliations

Molecular features of androgen-receptor low, estrogen receptor-negative breast cancers in the Carolina breast cancer study

Nikita D Jinna et al. Breast Cancer Res Treat. 2023 Sep.

Abstract

Purpose: Androgen receptor (AR) expression is absent in 40-90% of estrogen receptor (ER)-negative breast cancers. The prognostic value of AR in ER-negative patients and therapeutic targets for patients absent in AR remains poorly explored.

Methods: We used an RNA-based multigene classifier to identify AR-low and AR-high ER-negative participants in the Carolina Breast Cancer Study (CBCS; N = 669) and The Cancer Genome Atlas (TCGA; N = 237). We compared AR-defined subgroups by demographics, tumor characteristics, and established molecular signatures [PAM50 risk of recurrence (ROR), homologous recombination deficiency (HRD), and immune response].

Results: AR-low tumors were more prevalent among younger (RFD = + 10%, 95% CI = 4% to 16%) participants in CBCS and were associated with HER2 negativity (RFD = - 35%, 95% CI = - 44% to - 26%), higher grade (RFD = + 17%, 95% CI = 8% to 26%), and higher risk of recurrence scores (RFD = + 22%, 95% CI = 16.1% to 28%), with similar results in TCGA. The AR-low subgroup was strongly associated with HRD in CBCS (RFD = + 33.3%, 95% CI = 23.8% to 43.2%) and TCGA (RFD = + 41.5%, 95% CI = 34.0% to 48.6%). In CBCS, AR-low tumors had high adaptive immune marker expression.

Conclusion: Multigene, RNA-based low AR expression is associated with aggressive disease characteristics as well as DNA repair defects and immune phenotypes, suggesting plausible precision therapies for AR-low, ER-negative patients.

Keywords: Androgen receptor; Carolina breast cancer study; DNA repair; Estrogen receptor; Multigene signature; Triple-negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

The University of North Carolina, Chapel Hill has a license of intellectual property interest in GeneCentric Diagnostics and BioClassifier, LLC, which may be used in this study. The University of North Carolina, Chapel Hill may benefit from this interest that is/are related to this research. The terms of this arrangement have been reviewed and approved by the University of North Carolina, Chapel Hill Conflict of Interest Program in accordance with its conflict of interest policies.

Figures

Fig. 1
Fig. 1
RNA Expression of androgen receptor (AR) correlates with AR protein levels in The Cancer Genome Atlas (N = 872)
Fig. 2
Fig. 2
Kernel density estimates of androgen receptor (AR) expression according to estrogen receptor (ER) status in 1202 Carolina breast cancer study participants
Fig. 3
Fig. 3
Performance of expression-based low-androgen receptor (AR) classifier in estrogen receptor (ER)-negative samples in the Carolina breast cancer study (CBCS) samples A/B
See this image and copyright information in PMC

Update of

References

    1. Collins LC, et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol. 2011;24(7):924–931. doi: 10.1038/modpathol.2011.54. - DOI - PMC - PubMed
    1. Safarpour D, Tavassoli FA. A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers. Arch Pathol Lab Med. 2015;139(5):612–617. doi: 10.5858/arpa.2014-0122-RA. - DOI - PubMed
    1. Park S, et al. Expression of androgen receptors in primary breast cancer. Ann Oncol. 2010;21(3):488–492. doi: 10.1093/annonc/mdp510. - DOI - PubMed
    1. Micello D, et al. Androgen receptor is frequently expressed in HER2-positive ER/PR-negative breast cancers. Virchows Arch. 2010;457(4):467–476. doi: 10.1007/s00428-010-0964-y. - DOI - PubMed
    1. Gucalp A, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res. 2013;19(19):5505–5512. doi: 10.1158/1078-0432.CCR-12-3327. - DOI - PMC - PubMed